Vigil Neuroscience, Inc. announced a private placement of 537,634 Series A non-voting convertible preferred shares at a price of $7.44 per share for the gross proceeds of $3,999,996.96 on June 27, 2024. The transaction included participation from new investor, Sanofi Pasteur Biologics, LLC. Each share shall be convertible into ten shares of common stock.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4 USD | -10.71% |
|
+3.63% | +18.34% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.34% | 150M | |
+19.41% | 45.51B | |
+38.65% | 38.13B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- VIGL Stock
- News Vigil Neuroscience, Inc.
- Vigil Neuroscience, Inc. announced that it has received $3.999997 million in funding from Sanofi Pasteur Biologics, LLC